A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

This study is testing a treatment called R130, an oncolytic virus — a modified virus that is designed to infect and kill cancer cells while leaving healthy cells alone — for people with bone and soft tissue tumors (sarcomas) that have come back or stopped responding to standard treatments. **You may be eligible if...** - You are between 14 and 75 years old - You have a confirmed diagnosis of soft tissue sarcoma or a bone tumor - Standard treatments have failed, or you are unwilling or unable to receive other anti-cancer therapies - You are in reasonably good health (ECOG score 0–2) - Your life expectancy is at least 3 months - You have at least one measurable tumor that can be tracked on imaging **You may NOT be eligible if...** - You have active serious infections - You have severe organ damage (heart, liver, or kidneys) - You are pregnant or breastfeeding - You are taking medications that could interfere with the virus treatment - You have untreated or unstable brain metastases Talk to your doctor to see if this trial is right for you.